When is the next results date for Abbott India?

No Upcoming Board Meetings

Has Abbott India declared dividend?

Yes, Abbott India Ltd. has declared a dividend of 410% (₹410 per share) with an ex-date of July 19, 2024, resulting in a dividend yield of 1.3%. The company has shown strong total returns over various periods, with a total return of 104.28% over the last 4 years.

Abbott India Ltd. has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 4100%<BR>- Amount per share: 410 per share<BR>- Ex-date: 19 Jul 24<BR><BR>Dividend Yield: 1.3%<BR><BR>Total Returns by Period:<BR>In the last 6 months, Abbott India experienced a price return of 9.35% with no dividend return, resulting in a total return of 9.35%.<BR><BR>Over the past year, the company achieved a price return of 17.76% and a dividend return of 1.46%, leading to a total return of 19.22%.<BR><BR>In the 2-year period, Abbott India saw a price return of 45.62% and a dividend return of 2.56%, culminating in a total return of 48.18%.<BR><BR>For the 3-year period, the price return was 79.7% with a dividend return of 4.01%, resulting in a total return of 83.71%.<BR><BR>In the last 4 years, the company recorded a price return of 99.09% and a dividend return of 5.19%, achieving a total return of 104.28%.<BR><BR>Over the 5-year period, Abbott India had a price return of 86.07% and a dividend return of 6.21%, leading to a total return of 92.28%.<BR><BR>Overall, Abbott India has declared a substantial dividend, and the total returns across various periods indicate strong performance, particularly in price appreciation. The combination of high dividend yield and significant total returns reflects positively on the company's financial health.

Who are the peers of the Abbott India?

Abbott India's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Alkem Lab, GlaxoSmithKline Pharma, Glenmark Pharma, Biocon, and Ipca Labs. In terms of management risk, growth ratings, and capital structure, Abbott India ranks well, with a 1-year return of 19.13%, lower than Divi's Lab's 51.96% but higher than Alkem Lab's 3.75%.

Peers: Abbott India's peers are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Alkem Lab, Glaxosmi. Pharma, Glenmark Pharma, Biocon, and Ipca Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India, Dr Reddy's Labs, and Glaxosmi. Pharma, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Alkem Lab, and Ipca Labs, and Average management risk is present at Glenmark Pharma and Biocon. Growth ratings show Excellent growth at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average growth is noted at Abbott India and Ipca Labs, and Below Average growth is seen at Divi's Lab., Torrent Pharma, Alkem Lab, Glaxosmi. Pharma, Glenmark Pharma, and Biocon. Capital Structure is Excellent for Abbott India, Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Alkem Lab, and Glaxosmi. Pharma, Good for Glenmark Pharma, and Below Average for Biocon.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Alkem Lab has the lowest at 3.75%. Abbott India's 1-year return of 19.13% is higher than Alkem Lab's but lower than Divi's Lab.'s. Additionally, Torrent Pharma, Alkem Lab, Glenmark Pharma, and Biocon have negative six-month returns.

Is Abbott India overvalued or undervalued?

As of October 27, 2022, Abbott India is considered very expensive with a PE ratio of 47.32 and other high valuation metrics, indicating it is overvalued compared to peers like Sun Pharma and Cipla, despite its recent strong performance against the Sensex.

As of 27 October 2022, Abbott India's valuation grade moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently overvalued, with a PE ratio of 47.32, a Price to Book Value of 19.01, and an EV to EBITDA of 38.88. These ratios suggest that investors are paying a premium for the stock compared to its earnings and book value.<BR><BR>In comparison to its peers, Abbott India's valuation stands out as particularly high; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla is valued more attractively with a PE of 22.99. Additionally, Abbott's PEG ratio of 2.67 further emphasizes its overvaluation relative to peers like Divi's Lab, which has a PEG of 2.15. Despite outperforming the Sensex over various periods, including a 16% return over the past year compared to the Sensex's 7.63%, the current valuation metrics suggest that investors may be overestimating Abbott India's growth potential.

Who are in the management team of Abbott India?

As of March 2023, Abbott India's management team includes Munir Shaikh (Chairman), Vivek Vasudev Kamath (Managing Director), and several non-executive and independent directors, overseeing the company's strategic direction and governance.

As of March 2023, the management team of Abbott India includes the following members:<BR><BR>1. Munir Shaikh - Chairman (Non-Executive)<BR>2. Kaiyomarz Marfatia - Non Executive Director<BR>3. Ambati Venu - Non Executive Director<BR>4. Anisha Motwani - Independent Director<BR>5. Sudarshan Jain - Independent Director<BR>6. Shalini Kamath - Independent Director<BR>7. Sabina Ewing - Non Executive Director<BR>8. Vivek Vasudev Kamath - Managing Director<BR>9. Mahadeo Karnik - Director<BR><BR>This team is responsible for overseeing the company's strategic direction and governance.

What does Abbott India do?

Abbott India Ltd. is a leading multinational pharmaceutical company in India, with recent net sales of ₹16,046 Cr and a net profit of ₹3,670 Cr as of March 2025. It has a market cap of ₹73,197 Cr and key metrics include a P/E ratio of 51.00 and a dividend yield of 1.19%.

Overview: <BR>Abbott India Ltd. is a leading multinational pharmaceutical company in India, categorized as a Large Cap in the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Abbott India Ltd. was incorporated in an unspecified year and has maintained its status as a prominent player in the pharmaceutical sector. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>- Most recent Net Sales: 16,046 Cr (Quarterly Results - Mar 2025) <BR>- Most recent Net Profit: 3,670 Cr (Quarterly Results - Mar 2025) <BR>- Market-cap value: INR 73,197 Cr (Large Cap) <BR><BR>Key Metrics: <BR>- P/E: 51.00 <BR>- Industry P/E: 37 <BR>- Dividend Yield: 1.19% <BR>- Debt-Equity: -0.30 <BR>- Return on Equity: 40.17% <BR>- Price to Book: 20.72 <BR><BR>Contact Details: <BR>Address: Unit No 3 Corporate Park, Sion Trombay Road Chembur Mumbai Maharashtra : 400071 <BR>Tel: 91-22-67978888/50461000/2000/1119 <BR>Email: investorrelations.india@abbott.com <BR>Website: http://www.abbott.co.in

Who are the top shareholders of the Abbott India?

The top shareholder of Abbott India is Abbott Capital India Limited, holding 50.44%. Other significant shareholders include mutual funds with 7.77%, SBI Large & Midcap Fund at 2.66%, and individual investors with a combined 13.35%.

The top shareholders of Abbott India include Abbott Capital India Limited, which holds the largest stake at 50.44%. The company also has a diverse range of shareholders, including mutual funds, with 35 schemes collectively holding 7.77%. Additionally, there are 12 foreign institutional investors (FIIs) that hold 0.16% of the shares. The highest public shareholder is the SBI Large & Midcap Fund, which owns 2.66%. Individual investors collectively hold 13.35% of the company's shares.

How big is Abbott India?

As of 24th July, Abbott India Ltd. has a market capitalization of 73,832.00 Cr, with recent net sales of 6,409.15 Cr and a net profit of 1,414.44 Cr. The company has shareholder's funds of 4,233.15 Cr and total assets of 5,902.35 Cr as of March 2025.

As of 24th July, Abbott India Ltd. has a market capitalization of 73,832.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Abbott India reported Net Sales of 6,409.15 Cr and a Net Profit of 1,414.44 Cr.<BR><BR>For the latest annual period ending in March 2025, the company has Shareholder's Funds amounting to 4,233.15 Cr and Total Assets of 5,902.35 Cr.

Are Abbott India latest results good or bad?

Abbott India's Q2 FY26 results are strong, with a net profit of ₹415.27 crores and a 15.81% year-on-year growth, alongside improved operating margins at 28.58%. However, the stock has declined 9.62% in the past three months, raising concerns about its high valuation despite solid financial performance.

Abbott India's latest results for Q2 FY26 can be considered good overall. The company reported a net profit of ₹415.27 crores, which reflects a strong growth of 13.50% quarter-on-quarter and 15.81% year-on-year. Additionally, net sales reached ₹1,757.15 crores, showing a modest increase of 1.08% from the previous quarter and a healthy 7.62% growth compared to the same quarter last year.<BR><BR>One of the standout features of this quarter is the significant expansion in operating margins, which increased to 28.58%, the highest level in eight quarters. This improvement indicates effective cost management and strong pricing power in a competitive market. The return on equity (ROE) is also impressive at 34.31%, showcasing the company's capital efficiency.<BR><BR>However, it's important to note that despite these strong operational metrics, Abbott India's stock has faced challenges, declining 9.62% over the past three months while the broader market has advanced. This discrepancy suggests some investor concerns regarding the stock's elevated valuation, as it is trading at a high price-to-earnings ratio of 43 times trailing twelve-month earnings.<BR><BR>In summary, while Abbott India has demonstrated solid financial performance with strong profit and revenue growth, the stock's recent underperformance and high valuation multiples may warrant caution for investors.

How has been the historical performance of Abbott India?

Abbott India has shown consistent growth from March 2020 to March 2025, with net sales increasing from 4,093.14 crore to 6,409.15 crore, and profit after tax rising from 592.93 crore to 1,414.44 crore. Key financial metrics, including operating profit and earnings per share, have also significantly improved during this period.

Answer:<BR>Abbott India's historical performance shows a consistent growth trend in net sales, operating profit, and profit after tax over the past several years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Abbott India has demonstrated strong growth in net sales, increasing from 4,093.14 crore in March 2020 to 6,409.15 crore in March 2025. The total operating income followed a similar upward trajectory, reaching 6,409.15 crore in March 2025, up from 4,093.14 crore in March 2020. Operating profit (PBDIT) also saw significant growth, rising from 870.84 crore in March 2020 to 1,970.18 crore in March 2025. Profit before tax increased from 802.70 crore in March 2020 to 1,886.95 crore in March 2025, while profit after tax rose from 592.93 crore to 1,414.44 crore during the same period. The company's earnings per share (EPS) improved markedly from 279.03 in March 2020 to 665.62 in March 2025. Total assets grew from 3,532.41 crore in March 2020 to 5,902.35 crore in March 2025, reflecting a robust balance sheet. Cash flow from operating activities increased from 626.00 crore in March 2020 to 1,011.00 crore in March 2025, indicating strong operational efficiency. Overall, Abbott India has shown a solid financial performance with consistent growth across key metrics over the years.

Is Abbott India technically bullish or bearish?

As of December 2, 2025, the technical trend has shifted to a bearish stance, driven by bearish indicators like the weekly MACD and Bollinger Bands, despite some bullish momentum in the weekly RSI.

As of 2 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include the weekly MACD and Bollinger Bands both indicating bearish conditions, alongside bearish moving averages on the daily timeframe. Although the weekly RSI shows bullish momentum, it is overshadowed by the overall bearish signals from other indicators. The Dow Theory presents a mildly bullish view on the weekly chart, but this is not enough to counter the prevailing bearish trend.

Should I buy, sell or hold Abbott India?

Why is Abbott India falling/rising?

As of 04-Dec, Abbott India Ltd. is facing a stock price decline to 28,826.85, down 0.24%, and has underperformed its sector. The stock is in a bearish trend, trading below key moving averages, despite strong long-term fundamentals and a recent rise in delivery volume.

As of 04-Dec, Abbott India Ltd. is experiencing a decline in its stock price, currently at 28,826.85, which reflects a change of -68.0 or -0.24%. The stock has underperformed its sector by 0.53% today and has been on a consecutive fall for the last four days, resulting in a total decline of -4.13% during this period. <BR><BR>The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, despite a rise in delivery volume by 14.59% against the 5-day average, the overall performance remains weak. <BR><BR>Financially, the company has shown strong long-term fundamentals with an average Return on Equity (ROE) of 34.23% and healthy growth in operating profit at an annual rate of 16.97%. However, recent results have been flat, with the lowest Debt to Equity ratio and poor inventory and debtors turnover ratios, which may contribute to investor concerns. <BR><BR>Moreover, the stock's valuation appears expensive with a Price to Book Value of 15.3, despite a modest return of 0.10% over the past year, while profits have increased by 17.5%. These factors combined suggest that the stock's current decline is influenced by both recent performance metrics and valuation concerns.

Which are the latest news on Abbott India?